NOVO.B.DK

280.3

+4.2%↑

GMAB.DK

1,601

+0.38%↑

HLUNB.DK

44.64

+3.14%↑

ZEAL.DK

285.6

+4.85%↑

AMBUB.DK

63.75

-0.16%↓

NOVO.B.DK

280.3

+4.2%↑

GMAB.DK

1,601

+0.38%↑

HLUNB.DK

44.64

+3.14%↑

ZEAL.DK

285.6

+4.85%↑

AMBUB.DK

63.75

-0.16%↓

NOVO.B.DK

280.3

+4.2%↑

GMAB.DK

1,601

+0.38%↑

HLUNB.DK

44.64

+3.14%↑

ZEAL.DK

285.6

+4.85%↑

AMBUB.DK

63.75

-0.16%↓

NOVO.B.DK

280.3

+4.2%↑

GMAB.DK

1,601

+0.38%↑

HLUNB.DK

44.64

+3.14%↑

ZEAL.DK

285.6

+4.85%↑

AMBUB.DK

63.75

-0.16%↓

NOVO.B.DK

280.3

+4.2%↑

GMAB.DK

1,601

+0.38%↑

HLUNB.DK

44.64

+3.14%↑

ZEAL.DK

285.6

+4.85%↑

AMBUB.DK

63.75

-0.16%↓

Home・Lista de Ações・Coloplast A-S (Class B)

Coloplast A-S (Class B)

Abrir

380.8 0.47

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

377.3

Máximo

384.9

Indicadores-chave
By Trading Economics
Rendimento	-2.4B -971M
Vendas	41M 7.1B
P/E Médio do Setor	41.674 49.052
EPS	-0.16
Rendimento de Dividendos	5.99
Margem de lucro	-13.707
Funcionários	17,083
EBITDA	2.8B 5.1B

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+11.86% upside

Dividendos
By Acuity
Rendimento de Dividendos Médio do Setor	5.99% 2.36%

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-2.7B 88B
Abertura anterior	380.33
Fecho anterior	380.8

Coloplast A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

10 de jun. de 2026, 23:36 UTC

Correction to Oracle Reports Higher 4Q Profit Article

10 de jun. de 2026, 23:19 UTC

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 de jun. de 2026, 23:09 UTC

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 de jun. de 2026, 23:04 UTC

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 de jun. de 2026, 20:44 UTC

Caterpillar Raises Quarterly Dividend 8%

10 de jun. de 2026, 23:49 UTC

Elliott: Northern Star Should Take No Options Off The Table

10 de jun. de 2026, 23:48 UTC

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 de jun. de 2026, 23:48 UTC

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 de jun. de 2026, 23:47 UTC

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 de jun. de 2026, 23:47 UTC

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 de jun. de 2026, 23:46 UTC

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 de jun. de 2026, 23:38 UTC

Global Equities Roundup: Market Talk

10 de jun. de 2026, 23:38 UTC

Global Forex and Fixed Income Roundup: Market Talk

10 de jun. de 2026, 23:38 UTC

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 de jun. de 2026, 23:32 UTC

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 de jun. de 2026, 23:20 UTC

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 de jun. de 2026, 22:05 UTC

Correction to Bank of Canada Stays on Hold Market Talk

10 de jun. de 2026, 21:57 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:52 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:35 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 21:22 UTC

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 de jun. de 2026, 20:50 UTC

Tech, Media & Telecom Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Financial Services Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Basic Materials Roundup: Market Talk

10 de jun. de 2026, 20:50 UTC

Health Care Roundup: Market Talk

10 de jun. de 2026, 20:39 UTC

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 de jun. de 2026, 20:34 UTC

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 de jun. de 2026, 20:33 UTC

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 de jun. de 2026, 20:33 UTC

Global Equities Roundup: Market Talk

10 de jun. de 2026, 20:33 UTC

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparação entre Pares

Variação de preço

Coloplast A-S (Class B) Previsão

Preço-alvo

By TipRanks

11.86% parte superior

Previsão para 12 meses

Média 901.38 DKK 11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.